Connect with our team to design patient selection approaches that strengthen clinical trial outcomes.
By submitting this form, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may unsubscribe from these communications by following the unsubscribe link or the instructions provided in the communication we send. The information you submit is governed by our Privacy Notice and our website Terms of Use.
Contact Information
Without the right patient population, trials can fail to show efficacy, even when the therapy works.
We partner with you to design patient selection strategies that maximize the likelihood of clinical success.
A validated biomarker is only valuable if it translates into measurable clinical outcomes.
We help you connect biomarker insights to patient selection strategies that enable efficient enrollment, reduce variability, and strengthen signal detection in clinical trials.
We combine diagnostic expertise, global testing capabilities, and real-world experience to ensure the right patients are identified, enrolled, and stratified effectively.
Selecting the right patients starts with integrating diagnostics into trial design from the outset.
We help you:
So you can enroll the patients most likely to demonstrate therapeutic benefit
Variability in testing across geographies can compromise trial outcomes.
So your data remains reliable regardless of where patients are enrolled
Using established and validated diagnostics reduces uncertainty in patient selection.
So you can generate clearer signals and more robust clinical evidence
Enroll the wrong population and you risk missing your primary endpoint — costing years of development time and potentially the program itself.
Results of our tests can help:
Identify patients most likely to benefit from therapy
Enable efficient and targeted trial enrollment
Strengthen clinical signal detection to reduce the risk of missed endpoints
Our validated companion diagnostics support precise patient identification and trial enrichment reducing variability and strengthening confidence in clinical outcomes.
HRD Companion Diagnostic Test
Determines homologous recombination deficiency (HRD) status for patients with ovarian cancer using MyChoice CDx, the first and only FDA-approved, NGS-based IVD tumor test
Germline Companion Diagnostic Test
Identifies patients with deleterious or suspected deleterious mutations in BRCA1 or BRCA2 genes who may be eligible for certain targeted therapies, the first and only FDA-approved CDx test of its kind
Our global testing infrastructure ensures patients can be identified and tested consistently across regions, supporting reliable data generation and efficient trial execution.
The difference between a trial that hits its endpoint and one that doesn’t often comes down to whether the right patients were in the study.
Once your biomarker strategy is established, the next decisions determine whether your program can demonstrate real clinical impact.